<DOC>
	<DOCNO>NCT00568503</DOCNO>
	<brief_summary>This single dose Proof-of-Concept study mild-to-moderate COPD patient . The study investigate safety tolerability QAX028 well bronchodilatory effect QAX028 compare tiotropium placebo mild-to-moderate COPD patient .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacodynamics QAX028 Compared Open-label Tiotropium Bromide Placebo Mild-to-moderate Chronic Obstructive Pulmonary Disease ( COPD ) Patients .</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male female patient age 4075 year diagnosis mild moderate COPD Current Xsmokers smoke history &gt; 10 packyears . Screening ipratropium postbronchodilation FEV1 1 h postdose great 50 % normal predict FEV1 value . Patients comply follow washout period standard COPD treatment follow exclude : Shortacting bronchodilator Longacting bronchodilator Inhaled steroid Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>COPD/TIOTROPIUM/QAX028</keyword>
</DOC>